Molecules to Market (MtM) launches new herpes virus rapid test:
This article was originally published in Clinica
Executive Summary
Molecules to Market will launch the first rapid, point-of-care test for herpes simplex virus type 2 at the Congress of the European Academy of Dermatology and Venereology in Dublin this month. POCkit HSV 2 Rapid Test can specifically detect HSV 2 antigens in blood, enabling infection to be detected whether lesions are present or not, and gives results in 5-10 minutes. The kit will be marketed by MtM's Diagnology subsidiary.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.